Health problems most commonly diagnosed among young female patients during visits to general practitioners and gynecologists in France before the initiation of the human papillomavirus vaccination program

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 3, 2012, Pages 261-268

  van Ganse, Eric ^a   Letrilliart, Laurent ^b   Borne, Hélène ^c   Morand, Francois ^d   Robain, Matthieu ^d   Siegrist, Claire Anne ^e  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CSD ^*

^d Medical Faculty   (France)

^e UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Adverse events; Electronic health records; Health problems; Vaccines

Indexed keywords

ACNE; ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; BACKACHE; CHILD; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; DYSMENORRHEA; ELECTRONIC MEDICAL RECORD; FEMALE; FRANCE; GASTROINTESTINAL INFECTION; GENERAL PRACTITIONER; GENITAL CANDIDIASIS; GYNECOLOGIST; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; MULTICENTER STUDY; NERVOUSNESS; OUTCOME ASSESSMENT; PREGNANCY COMPLICATION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SCHOOL CHILD; SENSITIVITY ANALYSIS; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VACCINATION; WART VIRUS; WOMEN'S HEALTH;

ADOLESCENT; ADULT; CHILD; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; ELECTRONIC HEALTH RECORDS; FEMALE; FRANCE; GENERAL PRACTITIONERS; GENITAL DISEASES, FEMALE; GYNECOLOGICAL EXAMINATION; HUMANS; IMMUNIZATION PROGRAMS; LONGITUDINAL STUDIES; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RESPIRATORY TRACT INFECTIONS; YOUNG ADULT;

EID: 84858288128     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2243     Document Type: Article

References (18)

1. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56:1-24.
2. AFSSAPS (French Drug Agency). Risk Management Programme of Gardasil (in French). At. Accessed on March 31, 2011.
3. AFSSAPS (French Drug Agency). Gardasil: first assessment of risk surveillance in France. July 2008. At. Accessed on March 31, 2011.
4. AFSSAPS (French Drug Agency). Gardasil: second assessment of European and French Risk Management Programme. September 2009. At. Accessed on March 31, 2011.
5. Weisberg E, Bateson D, McCaffery K, Skinner SR. HPV vaccination catch up program - utilization by young Australian women. Aust Fam Physicians 2009; 38: 72-6.
6. Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J. 2007; 26:979-84.
7. Douglas RJ. Quadrivalent HPV vaccination reactions--more hype than harm. Aust Fam Physician. 2009; 38: 139-42.
8. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009; 302:750-757.
9. Collectif. Vaccin anti-HPV et cancer du col utérin [Review. HPV vaccine and uterus cancer]. Bibliomed 2007; 459.
10. Collectif. Vaccin anti-papillomavirus: balance bénéfices/risques. [Review. HPV vaccine: benefit-risk assessment]. Bibliomed 2009; 560.
11. Callréus T. Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning. Drug Saf. 2006; 29:557-66.
12. Okkes I, Oskam SK, Lamberts H. The probability of specific diagnoses for patients presenting with common symptoms to Dutch family physicians. J Fam Pract 2002; 51: 31-6.
13. Verbeke M, Schrans D, Deroose S, De Maeseneer J. The International Classification of Primary Care (ICPC-2): an essential tool in the EPR of the GP. Stud Health Technol Inform. 2006; 124:809-14.
14. Connolly JP, McGavock H, Wilson-Davis K. Research methodology: Coding perceived morbidity in general practice--an evaluation of the Read Classification and the International Classification of Primary Care (ICPC). Pharmacoepidemiol Drug Saf. 1997;6:325-30.
15. Black S, Eskola J, Siegrist CA, Halsey N, Macdonald N, Law B, Miller E, Andrews N, Stowe J, Salmon D, Vannice K, Izurieta HS, Akhtar A, Gold M, Oselka G, Zuber P, Pfeifer D, Vellozzi C. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2009;374: 2115-22. 31. Erratum in: Lancet. 2010; 375: 376.
16. Callréus T, Svanström H, Nielsen NM, Poulsen S, Valentiner-Branth P, Hviid A. Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events. Vaccine. 2009; 14: 2954-8.
17. Dourgnon P, Guillaume S, Naiditch M, Ordonneau C. Introducing Gate Keeping in France: first assessment of the preferred doctor scheme reform. QES 2007; 124: 1-4.
18. Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network - improving the evidence of medical-product safety. N Engl J Med 2009; 361:645-7.